Terms: = Prostate cancer AND NPM1, NPM, 4869, ENSG00000181163, P06748, B23, MGC104254 AND Treatment
10 results:
1. Focal therapy with high-intensity focused ultrasound for prostate cancer: 3-year outcomes from a prospective trial.
Kaufmann B; Raess E; Schmid FA; Bieri U; Scherer TP; Elleisy M; Donati OF; Rupp NJ; Moch H; Gorin MA; Mortezavi A; Eberli D
BJU Int; 2024 Apr; 133(4):413-424. PubMed ID: 37897088
[TBL] [Abstract] [Full Text] [Related]
2. Using Serological Proteome Analysis to Identify Serum Anti-Nucleophosmin 1 Autoantibody as a Potential Biomarker in European-American and African-American Patients With prostate cancer.
Dai L; Li J; Xing M; Sanchez TW; Casiano CA; Zhang JY
Prostate; 2016 Nov; 76(15):1375-86. PubMed ID: 27418398
[TBL] [Abstract] [Full Text] [Related]
3. mTOR transcriptionally and post-transcriptionally regulates npm1 gene expression to contribute to enhanced proliferation in cells with Pten inactivation.
Boudra R; Lagrafeuille R; Lours-Calet C; de Joussineau C; Loubeau-Legros G; Chaveroux C; Saru JP; Baron S; Morel L; Beaudoin C
Cell Cycle; 2016 May; 15(10):1352-62. PubMed ID: 27050906
[TBL] [Abstract] [Full Text] [Related]
4. Implication of npm1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer.
Destouches D; Sader M; Terry S; Marchand C; Maillé P; Soyeux P; Carpentier G; Semprez F; Céraline J; Allory Y; Courty J; De La Taille A; Vacherot F
Oncotarget; 2016 Oct; 7(43):69397-69411. PubMed ID: 26993766
[TBL] [Abstract] [Full Text] [Related]
5. Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers.
van der Poel H; Klotz L; Andriole G; Azzouzi AR; Bjartell A; Cussenot O; Hamdy F; Graefen M; Palma P; Rivera AR; Stief CG
World J Urol; 2015 Jul; 33(7):907-16. PubMed ID: 26037891
[TBL] [Abstract] [Full Text] [Related]
6. Regulatory role of nucleophosmin during the differentiation of human liver cancer cells.
Xu DH; Liu F; Li X; Chen XF; Jing GJ; Wu FY; Shi SL; Li QF
Int J Oncol; 2014 Jul; 45(1):264-72. PubMed ID: 24787960
[TBL] [Abstract] [Full Text] [Related]
7. PAI-1 induces cell detachment, downregulates nucleophosmin (b23) and fortilin (TCTP) in LnCAP prostate cancer cells.
Jankun J; Aleem AM; Specht Z; Keck RW; Lysiak-Szydlowska W; Selman SH; Skrzypczak-Jankun E
Int J Mol Med; 2007 Jul; 20(1):11-20. PubMed ID: 17549383
[TBL] [Abstract] [Full Text] [Related]
8. A role for radiotherapy in neuropathic bone pain: preliminary response rates from a prospective trial (Trans-tasman radiation oncology group, TROG 96.05).
Roos DE; O'Brien PC; Smith JG; Spry NA; Hoskin PJ; Burmeister BH; Turner SL; Bernshaw DM
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):975-81. PubMed ID: 10705020
[TBL] [Abstract] [Full Text] [Related]
9. In vitro and ex vivo expression of nucleolar proteins b23 and p120 in benign and malignant epithelial lesions of the prostate.
Bocker T; Bittinger A; Wieland W; Buettner R; Fauser G; Hofstaedter F; Rüschoff J
Mod Pathol; 1995 Apr; 8(3):226-31. PubMed ID: 7542384
[TBL] [Abstract] [Full Text] [Related]
10. Experience with neoadjuvant diethylstilboestrol and radical prostatectomy in patients with locally advanced prostate cancer.
Aprikian AG; Fair WR; Reuter VE; Sogani P; Herr H; Russo P; Sheinfeld J
Br J Urol; 1994 Nov; 74(5):630-6. PubMed ID: 7530128
[TBL] [Abstract] [Full Text] [Related]
